This event has closed.

Clinician Training to Screen and Assess for Fetal Alcohol Spectrum Disorders

This diagnostic skills-building training is targeted to those providers in a position to diagnose FASDs (physicians, nurse practitioners, physician assistants) and those who are part of a multidisciplinary or interdisciplinary team providing care for individuals at risk for FASDs (including children and youth, individuals in substance use disorder treatment, and individuals in the social service system with undiagnosed challenges).
 
This training is limited to physicians, nurse practitioners and physician assistants.
 
Learning Objectives
By the end of the training, clinicians should be able to:
  1. Define FASD and its component conditions, and explain its relevance to women’s treatment programs
  2. Describe the neurobehavioral and physical characteristics of FASDs
  3. Recognize and assess dysmorphic features associated with FASDs
  4. Explain FASD diagnostic criteria and the process of making a diagnosis
The Details
Format
Online
Date
On Demand

Activities

This training involves three activities:

1. Complete online CME course. This course takes approximately 2.5 hours. FASD: Current Concepts and Approaches (Access Here)
       

 2. Complete online CME course. This course takes approximately 1.5 hours. Assessing Dysmorphic Facial Features Associated with Prenatal Alcohol Exposure   (Access Here)          
3. View an interview with Dr. David Wargowski, MD answering the most common questions about screening, assessment, and diagnosis of FASDs. This video is approximately 30 minutes. (Access Here)​

There is no cost to participants for this training. ​
Funding for this website and programs were made possible (in part) by (Substance  Abuse Prevention & Treatment Block Grant H79T1085731​ funding.) from SAMHSA.

The views expressed in this website and materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. ​